Online inquiry

IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15419MR)

This product GTTS-WQ15419MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets LAG3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002286.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902
UniProt ID P18627
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15419MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2827MR IVTScrip™ mRNA-Anti-NGF, AMG-403(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG-403
GTTS-WQ12232MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ10766MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M-70
GTTS-WQ7661MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GEN-1029
GTTS-WQ3585MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAY 1112623
GTTS-WQ6697MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ3635MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ16013MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ZW-25
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW